![We present herein a 51-year-old man with a renal cell carcinoma diagnosed 8 years ago, initially treated with radical nephrectomy. Since then, and due to contralateral renal agenesis, the patient is dialyzed 3 times a week. During the last 6 years, he received multiple lines of systemic therapies (sunitinib, axitinib, everolimus, and nivolumab) with retroperitoneal lymph node and pleuropulmonary metastatic spread. Patient was referred to our department to perform an ^18^F-FDG PET/CT for response assessment 4 months after the start of nivolumab. At consultation before scan, patient presented with fatigue grade II and anorexia grade I, initially classified as adverse effects of nivolumab. FDG PET/CT demonstrated a complete metabolic response of pleural lesions, metabolically stable retroperitoneal and mediastinal lymph nodes, and a known left thyroid nodule (**A**, PET MIP images). Images also showed the appearance of multiple moderately hypermetabolic ground glass opacities (GGO) in both lungs of mainly peripheric distribution (**E--G**, axial PET, fused, and CT images), interlobular septal thickening also called "crazy paving" in the lingula (**B**--**D**, axial PET, fused, and CT images), and basal consolidation in the left lung with air bronchogram (**H**--**J**, axial PET, fused, and CT images). This pattern is highly suspicious for coronavirus disease 2019 (COVID-19) as previously reported.^[@bib1]^ However, nivolumab-induced pneumonitis can also present with similar findings on chest CT.^[@bib2]^ With these images, the patient was hospitalized for differential diagnosis, even if he presented no other previously reported frequent COVID-19 signs.^[@bib3]^ Nasopharyngeal swab test was performed, and blood test at admission showed increased LDH level (365 U/L) and decreased lymphocyte count (1.16 × 10^3^/mm^3^), which again could be related to both COVID-19 and nivolumab toxicity. C-reactive protein levels were high (167 mg/L), which finally oriented toward the infectious hypothesis. At 24 hours, RT-PCR (reverse transcription polymerase chain reaction) confirmed a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and hydroxychloroquine and piperacillin/tazobactam treatment was started. Within a few months, COVID-19 has become a pandemic with more than 2 million patients infected with SARS-CoV-2 and a mortality rate of 3.4%.^[@bib4]^ Oncologic patients are at higher risk for severe clinical events, mainly due to frequent comorbidities and compromised immune system, with a case fatality rate of 5.6% compared with 2.3% in the general population.^[@bib5]^ Early diagnosis is crucial in order to rapidly apply isolation measures and avoid nosocomial spread in cancer clinics. However, frequent unspecific clinical presentation and a false-negative rate of up to 30% for nasopharyngeal swab RT-PCR can delay diagnosis.^[@bib6]^ When performing routine PET/CT during COVID-19 pandemic, special and systematic attention should be given to the lung images before discharging the patient, as previously unsuspected active disease could be easily detected in asymptomatic patients.^[@bib7]^ This case illustrates the added complexity of COVID-19 diagnosis in cancer patients, particularly while on active treatment with immunotherapy, as adverse effects of checkpoint inhibitors can present with similar clinical and radiological findings. Indeed, both conditions can induce interstitial lung opacities consisting of massive amounts of activated immune cells, which are highly hypermetabolic on FDG PET.^[@bib8],[@bib9]^](rlu-publish-ahead-of-print-10.1097.rlu.0000000000003152-g001){#FU1}
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